While Alnylam Pharmaceuticals Inc has underperformed by -0.19%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ALNY rose by 56.06%, with highs and lows ranging from $304.39 to $141.98, whereas the simple moving average fell by -11.01% in the last 200 days.
On March 31, 2025, Redburn Atlantic started tracking Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) recommending Buy. A report published by JP Morgan on March 24, 2025, Upgraded its rating to ‘Overweight’ for ALNY. Goldman August 16, 2024d its ‘Neutral’ rating to ‘Buy’ for ALNY, as published in its report on August 16, 2024. Goldman’s report from February 16, 2024 suggests a price prediction of $173 for ALNY shares, giving the stock a ‘Neutral’ rating. Wolfe Research also rated the stock as ‘Peer Perform’.
Analysis of Alnylam Pharmaceuticals Inc (ALNY)
Further, the quarter-over-quarter increase in sales is 34.90%, showing a positive trend in the upcoming months.
One of the most important indicators of Alnylam Pharmaceuticals Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. Taking into account the quick ratio of the company, currently set at 2.71, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and ALNY is recording 898.38K average volume. On a monthly basis, the volatility of the stock is set at 6.85%, whereas on a weekly basis, it is put at 6.34%, with a loss of -5.25% over the past seven days. Furthermore, long-term investors anticipate a median target price of $318.79, showing growth from the present price of $230.50, which can serve as yet another indication of whether ALNY is worth investing in or should be passed over.
How Do You Analyze Alnylam Pharmaceuticals Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 4.40%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 95.68% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
ALNY shares are owned by institutional investors to the tune of 95.68% at present.
